Abstract
Hyperuricemia in hypertensive subjects has been considered one of risk factors of cardiovascular diseases. We investigated the status of uric acid management in 799 hypertensive subjects (432 females and 367 males; mean age 70.9 years) managed by 43 doctors (19 cardiologists and 24 noncardiologists; 25 private practice doctors and 18 hospital doctors). The serum uric acid level was available in 85.7% of the patients. This availability was equivalent regardless of facility size, and more cardiologists than noncardiologists monitored this information. The prevalence of hyperuricemia was 17.5% and was higher in men and in patients with high triglyceridemia, left ventricular hypertrophy, renal dysfunction, proteinuria, and smokers, but was not higher in subjects with chronic heart failure, diabetes mellitus, and those with prescriptions for diuretics and β-blockers. The average serum uric acid level was higher in men and patients with chronic heart failure, renal dysfunction, high triglyceridemia, low high-density cholesterolemia, smokers, and subjects prescribed β-blockers. Fifty percent of hyperuricemic patients were medicated, and 48.6% of them cleared the uric acid target level (6 mg/dL). No differences were observed in the treatment rate or the achievement rate of the target between genders, concurrent diseases, and physician specialties. Although doctors, especially cardiologists, have a high concern for the serum uric acid level, they do not intervene intensively, and specific treatment for individual patterns is not routinely given. Thus, more attention to uric acid management is necessary in hypertensive subjects to prevent cardiovascular diseases.
Similar content being viewed by others
Article PDF
References
Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH : Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 275: 457–464.
Johnson RJ, Kang DH, Feig D, et al: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183–1190.
Culleton BF, Larson MG, Kannel WB, Levy D : Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7–13.
Freedman DS, Williamson DF, Gunter EW, Byers T : Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-Up Study. Am J Epidemiol 1995; 141: 637–644.
Alderman MH, Cohen H, Madhavan S, Kivlighn S : Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144–150.
Tomita M, Mizuno S, Yamanaka H, et al: Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000; 10: 403–409.
Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P : Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072–1078.
Franse LV, Pahor M, Di Bari M, et al: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149–1154.
Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L : Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001; 37: 1069–1074.
Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS : Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28–33.
Mazzali M, Hughes J, Kim YG, et al: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101–1106.
Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL : Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 2005; 45: 34–38.
Yamamoto Y, Ogino K, Igawa G, et al: Allopurinol reduces neointimal hyperplasia in the carotid artery ligation model in spontaneously hypertensive rats. Hypertens Res 2006; 29: 915–921.
Rao GN, Corson MA, Berk BC : Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991; 266: 8604–8608.
Committee for the Preparation of Guidelines for the Management of Hyperuricemia and Gout, Japanese Society of Gout and Nucleic Acid Metabolism : Guidelines for the Management of Hyperuricemia and Gout. Tokyo, Japanese Society of Gout and Nucleic Acid Metabolism, 2002.
Yamamoto Y, Sonoyama K, Matsubara K, et al: The status of hypertension management in Japan in 2000. Hypertens Res 2002; 25: 717–725.
ALLHAT Investigators : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.
Mori H, Ukai H, Yamamoto H, et al: Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143–151.
Hoieggen A, Alderman MH, Kjeldsen SE, et al: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041–1049.
Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y : Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006; 47: 195–202.
Anker SD, Doehner W, Rauchhaus M, et al: Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991–1997.
Doehner W, Schoene N, Rauchhaus M, et al: Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105: 2619–2624.
Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD : Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221–226.
Japan Atherosclerotic Society : Japan Atherosclerotic Society (JAS) Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Disease. Tokyo, Japan Atherosclerotic Society, 2002.
Ohtahara A, Hisatome I, Yamamoto Y, et al: The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and alpha1-blockers. J Hypertens 2001; 19: 575–582.
Nagahama K, Iseki K, Inoue T, Touma T, Ikemiya Y, Takishita S : Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27: 227–233.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamamoto, Y., Matsubara, K., Igawa, G. et al. Status of Uric Acid Management in Hypertensive Subjects. Hypertens Res 30, 549–554 (2007). https://doi.org/10.1291/hypres.30.549
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1291/hypres.30.549
Keywords
This article is cited by
-
Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia
Hypertension Research (2017)